Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: Results from an intergroup phase II trial

Journal of Clinical Oncology

Volumn 21, Issue 7, 2003, Pages 1313-1319

  Rothenberg, Mace L ^a   Liu, P Y ^a   Braly, Patricia S ^a   Wilczynski, Sharon P ^a   Hannigan, Edward V ^a   Wadler, Scott ^a   Stuart, Gavin ^a   Jiang, Caroline ^a   Markman, Maurie ^a   Alberts, David S ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FATIGUE; FEMALE; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALAISE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING; ADENOCARCINOMA; ADULT; AGED; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG TOLERANCE; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; OVARY TUMOR; RECTAL DRUG ADMINISTRATION;

ADENOCARCINOMA; ADMINISTRATION, RECTAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG TOLERANCE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0038514118     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.07.031     Document Type: Article

References (31)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
2. Bristow RE, Tomacruz RS, Armstrong DK, et al: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 20:1248-1259, 2002
3. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
4. Ozols RF, Bundy BN, Fowler J, et al: Randomized phase III study of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal stage III epithelial ovarian cancer: A Gynecologic Oncology Group trial (GOG 158). Proc Am Soc Clin Oncol 18:356a, 1999 (abstr 1373)
5. Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007, 2001
6. Gadducci A, Carnino F, Chiara S, et al: Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: A randomized trial of the Gruppo Oncologico Nord-Ouest. Gynecol Oncol 76:157-162, 2000
7. Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699-708, 2000
8. Dedrick RL, Myers CE, Bungay PM, et al: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1-11, 1978
9. Dedrick RL, Flessner MF: Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J Natl Cancer Inst 89:480-487, 1997
10. Howell SB, Pfeifle CL, Wung WE, et al: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845-851, 1982
11. Markman M, Rowinsky E, Hakes T, et al: Phase I trial of intraperitoneal Taxol: A Gynecologic Oncology Group study. J Clin Oncol 10:1485-1491, 1992
12. Schneider JG: Intraperitoneal chemotherapy. Obstet Gynecol Clin North Am 21:195-212, 1994
13. Markman M, Reichman B, Hakes T, et al: Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 10:1479-1484, 1992
14. Francis P, Rowinsky E, Schneider J, et al: Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study. J Clin Oncol 13:2961-2967, 1995
15. Kirmani S, Lucas WE, Kim S, et al: A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian cancer. J Clin Oncol 9:649-657, 1991
16. Markman M: Intraperitoneal therapy of ovarian cancer. Semin Oncol 25:356-360, 1998
17. Hofstra LS, de Vries EGE, Mulder NH, et al: Intraperitoneal chemotherapy in ovarian cancer. Cancer Treat Rev 26:133-143, 2000
18. Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955, 1996
19. Favalli G, Odicino F, Pecorelli S: Surgery of advanced malignant epithelial tumours of the ovary. Forum (Genova) 10:312-320, 2000
20. Gordon AN, Granai CO, Rose PG, et al: Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18:3093-3100, 2000 21. McGuire WP, Blessing JA, Bookman MA, et al: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 18:1062-1067, 2000
21. Shapiro JD, Millward MJ, Rischin D, et al: Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 63:89-93, 1996
22. van der Burg MEL, van Lent M, Buyse M, et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332:629-634, 1995
23. Rose PG, Nerenstone S, Brady M, et al: A Phase III randomized trial of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 21:201a, 2002 (abstr 802)
24. Levin L, Hryniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5:756-767, 1987
25. Ngan HY, Choo YC, Cheung M, et al: A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer: Hong Kong Ovarian Carcinoma Study Group. Chemotherapy 35:221-227, 1989
26. McGuire WP, Hoskins WJ, Brady MF, et al: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 13:1589-1599, 1995
27. Conte PF, Bruzzone M, Carino F, et al: High dose versus low dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: A randomized study of the Gruppo Oncologico Nord-Ouest. J Clin Oncol 14:351-356, 1996
28. McGuire WP: Intraperitoneal therapy for ovarian cancer: A sacrifice bunt. J Clin Oncol 19:921-923, 2001
29. Ries LAG, Eisner MP, Kosary CL, et al (eds): SEER Cancer Statistics Review, 1973-1999. National Cancer Institute, Bethesda, MD. Http://seer.cancer. gov/csr/1973_1999/
30. Barakat RR, Sabbatini P, Bhaskaran D, et al: Intraperitoneal chemotherapy for ovarian carcinoma: Results of long-term follow-up. J Clin Oncol 20:694-698, 2002
31. Armstrong DK, Bundy BN, Baergen R, et al: Randomized phase III study of intravenous paclitaxel and cisplatin versus intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in optimal stage III epithelial ovarian cancer: A Gynecology Oncology Group trial (GOG-172). Proc Am Soc Clin Oncol 21:201a, 2002 (abstr 803)